异基因造血干细胞移植后的免疫格局:表达TIGIT和CD161的CD4 T细胞与后续白血病复发相关
该研究用质谱流式细胞术全面刻画异基因造血干细胞移植(allo-HSCT)后患者循环白细胞的免疫调控格局,发现移植后3至6个月免疫格局稳定而6至12个月变化较多,移植后1年免疫平衡仍与健康人存在深刻差异;在第二个横断面队列中,移植后3个月CD4 T细胞上高水平的TIGIT和CD161表达与后续急性髓系白血病(AML)复发显著相关。
要点
- 移植后3至6个月免疫格局稳定,6至12个月出现较多变化。
- 移植后1年免疫平衡与健康人相比仍存在深刻改变。
- 移植后3个月CD4 T细胞高表达TIGIT和CD161与后续AML复发显著相关。
核心结论
- 移植后3个月CD4 T细胞上高水平的TIGIT和CD161表达是与后续AML复发显著相关的特征。
- 这些数据为移植后免疫调控格局的重建提供整体认识,并提示与复发相关的非经典抑制性受体可能开辟新的预后工具或治疗靶点。
研究设计与样本
- 研究采用质谱流式细胞术全面刻画异基因造血干细胞移植(allo-HSCT)后患者循环白细胞。
- 研究纳入2个allo-HSCT后患者队列,其中一个队列进行纵向评估,另一个为横断面队列。
主要发现
- 纵向评估显示免疫调控参数呈现特定趋势,例如髓源性抑制细胞(MDSC)与调节性T细胞(Treg)呈相反的动态变化。
- 免疫格局在移植后3至6个月稳定,而移植后6至12个月出现许多变化。
- 与健康个体比较显示,移植后1年免疫平衡的深刻改变持续存在。
- 在第二个横断面队列中,移植后3个月CD4 T细胞上高水平的TIGIT和CD161表达与后续AML复发显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment for selected patients with acute myeloid leukemia (AML) and relies on a "graft-versus-leukemia" effect (GVL) where donor T lymphocytes mediate control of malignant cell growth. However, relapse remains the major cause of death after allo-HSCT. In various malignancies, several immunoregulatory mechanisms have been shown to restrain antitumor immunity, including ligand-mediated engagement of inhibitory receptors (IRs) on effector cells, and induction of immunosuppressive cell subsets, such as regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs). Relapse after HSCT remains a major therapeutic challenge, but immunoregulatory mechanisms involved in restraining the GVL effect must be better deciphered in humans. We used mass cytometry to comprehensively characterize circulating leukocytes in 2 cohorts of patients after allo-HSCT. We first longitudinally assessed various immunoregulatory parameters highlighting specific trends, such as opposite dynamics between MDSCs and Tregs. More generally, the immune landscape was stable from months 3 to 6, whereas many variations occurred from months 6 to 12 after HSCT. Comparison with healthy individuals revealed that profound alterations in the immune equilibrium persisted 1 year after HSCT. Importantly, we found that high levels of TIGIT and CD161 expression on CD4 T cells at month 3 after HSCT were distinct features significantly associated with subsequent AML relapse in a second cross-sectional cohort. Altogether, these data provide global insights into the reconstitution of the immunoregulatory landscape after HSCT and highlight non-canonical IRs associated with relapse, which could open the path to new prognostic tools or therapeutic targets to restore subverted anti-AML immunity.
引用
- Gournay V, Vallet N, Peux V, et al. Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood. 2022. PMID: 35820057. doi:10.1182/blood.2022015522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。